Actively Recruiting
Study of Superselective Adrenal Arterial Embolization to Treat Essential Refractory Hypertension Evaluating Safety and Effectiveness with 8-Week Follow-Up
Led by Second Affiliated Hospital of Nanchang University · Updated on 2024-08-23
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This study focuses on patients with essential refractory hypertension, a condition where high blood pressure remains uncontrolled despite treatment. Researchers aim to assess the safety and effectiveness of a procedure called superselective adrenal arterial embolization SAAE for these patients. The study is designed as a single-center, open-label, self-controlled, and prospective trial to explore the potential of SAAE in managing primary refractory hypertension. Participants will undergo the SAAE procedure, which involves injecting an embolic agent through a catheter into the adrenal artery to block part of the adrenal gland. This aims to reduce adrenal hormone secretion and potentially lower blood pressure. After the procedure, patients will be closely monitored during an 8-week follow-up period to evaluate treatment safety and effects. Throughout the study, participants will have their 24-hour mean systolic and diastolic blood pressure measured 8 weeks after SAAE. Researchers will also track the proportion of patients who no longer have refractory hypertension. Safety will be assessed by monitoring procedure-related complications, adrenal hormones, kidney function, and plasma electrolyte levels during the 8 weeks following treatment. The total involvement includes the procedure and the subsequent 8-week observation period.
CONDITIONS
Brief Title
Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study
Research Team
Y
Yifei the second affiliated hospital of Nanchang university, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here